Weight-loss programs, including interventional, pharmaceutical, and dietary strategies, improve survival chances and cardiac function in individuals with concurrent obesity and heart failure.
Do weight-loss programs improve cardiac function and survival in individuals with heart failure and obesity?
Weight-loss interventions (dietary, pharmaceutical, and interventional) are highlighted as beneficial for improving survival and cardiac function in patients with concurrent obesity and heart failure.
Obesity can cause the onset of heart failure and exacerbate the status of the pre-existing disease. Through intricate pathways, obesity activates hormonal factors that encourage the development of inflammation and lead to increased congestion. Consequently, this complex parallel pathophysiological cascade contributes to the echocardiographic and clinical signs of heart failure. In these patients, obesity frequently coexists with nutritional and muscular profile abnormalities that manifest as cachexia or sarcopenia. Patients with heart failure have a higher chance of surviving when obesity is treated. Interventional, pharmaceutical, and dietary strategies are used as forms of therapy. This review delves into the evaluation of the relationship between obesity and heart failure, and it targets to highlight the therapeutical impact of weight-loss programs on cardiac function in individuals with heart failure and obesity.
Manta et al. (Thu,) conducted a review in Obesity and Heart Failure. Weight-loss programs was evaluated. Weight-loss programs, including interventional, pharmaceutical, and dietary strategies, improve survival chances and cardiac function in individuals with concurrent obesity and heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: